George (Beijing) Clinical Research Co., Ltd.

1 Primary Objective The primary objective of this study is to evaluate the safety and tolerability of povetacicept in healthy adult subjects from China or Japan. 2 Secondary Objectives The secondary objectives of this study are: To evaluate the PK of povetacicept. To evaluate the PD of povetacicept. To evaluate the incidence of anti-povetacicept ADA.

Primary Objectives: To evaluate the effect of BLU-5937 on 24-hour cough frequency at Week 24 compared to placebo in adult patients with RCC (including chronic cough of unknown etiology) with a baseline 24-hour cough frequency ≥8 coughs/hour and to determine the safety of BLU-5937 compared to placebo in adult patients with RCC (including chronic cough of unknown etiology) as of Week 24 Secondary Objectives: To evaluate the effect of BLU-5937 on other measures, including cough frequency and PROs Exploratory Objectives: To evaluate the effect of BLU-5937 on other measures, including cough frequency and PROs